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OBJECTIVE — The economic costs of hyperglycemia are substantial. Early detection would
allow management to prevent or delay development of diabetes and diabetes-related complica-
tions. We investigated the economic justiﬁcation for screening for pre-diabetes/diabetes.
RESEARCH DESIGN AND METHODS — We projected health system and societal
costs over 3 years for 1,259 adults, comparing costs associated with ﬁve opportunistic screening
tests. All subjects had measurements taken of random plasma and capillary glucose (RPG and
RCG), A1C, and plasma and capillary glucose 1 h after a 50 g oral glucose challenge test without
priorfasting(GCT-plandGCT-cap),andasubsequentdiagnostic75goralglucosetolerancetest
(OGTT).
RESULTS — Assuming 70% speciﬁcity screening cutoffs, Medicare costs for testing, retail
costsforgenericmetformin,andcostsforfalsenegativesas10%ofreportedcostsassociatedwith
pre-diabetes/diabetes, health system costs over 3 years for the different screening tests would be
GCT-pl $180,635; GCT-cap $182,980; RPG $182,780; RCG $186,090; and A1C $192,261; all
lower than costs for no screening, which would be $205,966. Under varying assumptions,
projected health system costs for screening and treatment with metformin or lifestyle modiﬁca-
tion would be less than costs for no screening as long as disease prevalence is at least 70% of that
of our population and false-negative costs are at least 10% of disease costs. Societal costs would
equal or exceed costs of no screening depending on treatment type.
CONCLUSIONS — Screening appears to be cost-saving compared to no screening from a
health system perspective, and potentially cost-neutral from a societal perspective. These data
suggestthatstrongconsiderationshouldbegiventoscreening—withpreventivemanagement—
and that use of GCTs may be cost-effective.
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T
he prevalence and costs associated
with diabetes and pre-diabetes chal-
lenge the ﬁnancial integrity of our
healthcare systems. However, screening
would allow management aimed at pre-
venting or delaying development of dia-
betes and complications and could
possibly reduce costs. Recommendations
regarding screening for pre-diabetes and
diabeteshavebeenmadebytheAmerican
Diabetes Association (ADA) (1), but for-
malscreeningisinfrequent(2).Screening
options include fasting plasma glucose
(FPG) and oral glucose tolerance tests
(OGTTs), but both require fasting sam-
ples that patients ﬁnd inconvenient (3),
and it is not clear what the best screening
strategy is—another reason screening is
under-performed (4). There is also con-
troversy as to whether screening for dia-
betes is cost-effective (5). Previous
analyses of the costs of screening have of-
ten focused only on diabetes, have not
compared different screening strategies,
or have examined screening in only lim-
ited ways, e.g., have not included the
downstream implications of detecting di-
abetes as well as pre-diabetes or have ig-
noredthecostsoffalse-negativeandfalse-
positive screening results (6–12).
We evaluated the economic justiﬁca-
tion for screening for diabetes and pre-
diabetes. We estimated the costs of
screening with random plasma or capil-
lary glucose (RPG or RCG) and A1C tests,
informal screening tests frequently used
in routine practice, and a glucose chal-
lenge test (GCT) approach similar to that
used to screen for gestational diabetes,
along with the costs of management. Our
objectives were to determine whether
screeningcoupledwith3yearsofpreven-
tive management is likely to be cost-
effective compared with no screening,
and if there is an optimal screening strat-
egy from an economic perspective.
RESEARCH DESIGN AND
METHODS— The study was ap-
proved by the Emory University Institu-
tional Review Board and utilized data
from1,259adultsintheScreeningforIm-
paired Glucose Tolerance (SIGT) study,
described previously (13). Brieﬂy, this
study recruited participants without
known diabetes between January 2005
and March 2008. The subjects’ ﬁrst visit
was at different times of the day, without
an overnight fast. Random capillary and
plasma glucose (RCG and RPG) were
measured,a50gglucosedrinkwasgiven,
andcapillaryandplasmaglucose1hafter
a 50 g oral glucose challenge test (GCT-
capandGCT-pl)weremeasured.Atasec-
ond visit, after an overnight fast, A1C was
drawnanda75gOGTTwasbegunbefore
11:00 A.M.
Case deﬁnitions
Based on glucose levels that confer in-
creased mortality, pre-diabetes included:
1) impaired fasting glucose110 (IFG110),
fasting glucose 110–125 mg/dl and 2-h
OGTT glucose 140 mg/dl; 2) impaired
glucose tolerance (IGT), fasting glucose
110mg/dland2-hOGTTglucose140–
199 mg/dl; and 3) IFG110 with IGT
(IFGIGT), fasting glucose 110–125
mg/dl and 2-h OGTT glucose 140–199
mg/dl(14).Diabetesincludedfastingglu-
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cose 200 mg/dl.
Screening test characteristics
Sensitivities and speciﬁcities were calcu-
lated at different cutoffs, and receiver op-
erating characteristic (ROC) curves were
generated using logistic regression. All
statistical analyses were performed using
SAS, version 9.1 (SAS Institute, Cary,
NC).
Screening test cutoffs
Cutoffs were based on sensitivity and
speciﬁcity, as well as the optimality crite-
rion(whereROCcurveslope[marginal
cost of false positives/marginal cost of
false negatives]  [prevalence of no dis-
ease/prevalence of disease]) (15). Our
basecaseanalysesutilized70%speciﬁcity
cutoffs, as higher-speciﬁcity cutoffs are
thought to be cost-effective (5).
Cost assessment
Costs were expressed in 2007 U.S. dol-
lars. Health system costs were assessed
fromaCentersforMedicareandMedicaid
Services (CMS)-as-payer perspective—
thusreﬂectingthetypesandlevelsofcosts
that would be incurred in the Medicare
fee for service program—and compared
with Veterans Administration (VA) costs,
to provide a single-payer perspective. In-
cludedwerethedirectmedicalcostsasso-
ciated with screening, the costs of false
negatives, and the costs for true positive
cases of pre-diabetes and diabetes. Soci-
etalcostsincludedboththedirectmedical
anddirectnonmedicalcostsoftesting,di-
rect and indirect (lost labor productivity)
costs of false negatives, and direct medi-
cal, direct nonmedical, and indirect costs
of true positives. Base case assumptions
are outlined below. Cost components for
theseanalysesareprovidedinmoredetail
in the online appendix available at http://
care.diabetesjournals.org/cgi/content/full/
dc10-0054/DC1.
Costs of testing
CMS-based direct costs of testing in-
cluded costs for laboratory tests, cost of
the GCT glucose drink, and staff costs. It
wasassumedthatbloodforGCT-pl,RPG,
and OGTT would be drawn at an on-site
laboratory. The direct nonmedical costs
of testing reﬂected excess time spent by
the patient. Since screening was assumed
to be opportunistic (during a visit), the
visit time was not included.
Costs of false negatives
For the base case analyses, the cost of a
false negative (pre-diabetes or diabetes
that was undetected) was evaluated as
10% of the projected marginal 3-year
medical costs for that condition, assum-
ingthatmarginalcostscouldbedecreased
byappropriatemanagement,astheywere
intheDiabetesPreventionProgram(DPP)
(16,17). The cost of a false negative was
assumedtoincludethe3-yeardirectmed-
ical cost of diabetes, pre-diabetes, and/or
pre-diabetes that progressed to diabetes.
Direct medical costs for diabetes were
based on Medical Expenditure Panel Sur-
vey costs from 2000–2004, which came
to $4,174/year in 2005 U.S. dollars for a
50-year-old person with new-onset dia-
betes (18). Patients with IFG110 in Kaiser
Permanente Northwest had marginal di-
rect medical costs of $1,316/year (19),
used for all patients with pre-diabetes (al-
though IGT might incur higher costs
[14,20]). In the DPP, treatment with met-
formin and lifestyle changes reduced
medical costs outside of the study by
5–9% (16). Since the DPP participants
were all receiving medical follow-up
through the study, the cost impact would
likely be greater in the general popula-
tion, in which close medical care for
missed diagnoses would be lacking; 10%
of projected costs was assigned as a rea-
sonable amount that might be reduced by
detection of the condition. A 3-year time
period for the estimation of cost was cho-
sen, because this is the period over which
DPP costs were calculated and is also the
time between ADA-recommended
screenings.
Indirect costs for false negatives (ab-
senteeism, reduced productivity at work,
and unemployment) were derived from
the ADA 2007 economic assessment and
were attributed only to those with diabe-
tes or whose pre-diabetes progressed to
diabetes during the 3 years (21).
Costs of true positives
Direct medical costs for a true positive
were based on 3-year costs for the DPP
metformin group, in which marginal
costs for laboratory tests, physician visits,
and follow-up were $703 (17); we substi-
tuted current generic costs for metformin
850 mg twice a day. Direct medical costs
incurred outside of the study, direct non-
medical costs, and indirect costs for the
DPPmetforminversusplaceboarmswere
used as other components for the cost of
true positives (17); direct medical costs
outside the study were $329 for the
metformin versus placebo arms. Societal
costs included 3-year direct nonmedical
costs ($11) and indirect costs ($278) in
the metformin versus placebo arms.
Sensitivity analyses
Screening cutoffs. We considered alter-
native cutoffs for a positive screen: 90%
sensitivity cutoffs, as well as cutoffs based
on the optimality criterion (above).
Testing. We evaluated 5 and 10 min
of additional staff time for all tests. Addi-
tional patient time was also considered:
10minforcapillarytestingand30minfor
plasma testing.
Disease prevalence. We considered
prevalences 50% higher and 50% lower
than those in the study population.
Rates of progression to diabetes. We
considered a higher risk of progression
from pre-diabetes to diabetes, 10% per
year with IFG110 or IGT, and 15% per
year for IFGIGT. False negatives: 1)W e
assessed the impact of preventing frac-
tions of direct medical costs ranging from
1–40%; 2) We examined DPP false-
negative costs, which were $329 (the
costs incurred by the placebo group out-
side of the DPP study), using this value
(based on IGT with fasting glucose 95
mg/dl) for pre-diabetes, and twice this
cost, $658, for diabetes. For alternative
societal costs, indirect costs were based
on the ADA economic analysis and taken
conservatively as $68 over 3 years, which
is our estimate of ADA’s indirect costs for
patients with pre-diabetes (online appen-
dix Table A1) and twice this for patients
with diabetes (21).
VA healthcare system. We evaluated
VA testing costs. Allowing for costs 50%
above those of metformin itself, we eval-
uated an alternative true positive (VA-TP)
cost of $165 per true positive over 3 years
(approximately one-third of base case
treatment costs). We also considered
VA-TP alternative direct nonmedical and
indirect costs to be approximately one-
third of the direct nonmedical and indi-
rectcostsfortreatmentwithmetforminin
the DPP study, $90 combined (online
appendix Table A1).
Lifestyle treatment. We evaluated
costs of treatment with lifestyle modiﬁca-
tion using DPP-based costs, assuming
group intervention costs and costs for
other lifestyle changes as described in the
DPP protocol (17).
RESULTS— The subjects had an aver-
age age of 48 years and BMI 30 kg/m
2;
they were 55% African American and
Chatterjee and Associates
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(3.5% IFG110 only, 12.5% IGT only, and
3.5% IFGIGT), and 4.9% had diabetes.
Dysglycemia (previously unrecognized
pre-diabetes and diabetes) was present in
24.5%, and as reported previously (13)
was identiﬁed with greatest accuracy by
GCT-pl and least well by RCG. For the
different tests, 70% speciﬁcity cutoffs
(true positives, and false negatives), re-
spectively, would be: GCT-pl 138 mg/dl
(248, 61); GCT-cap 162 mg/dl (214, 95);
RPG 100 mg/dl (195, 114); RCG 106
mg/dl (156, 153); A1C 5.5% (202, 107).
Table1showsbasecasehealthsystem
and societal cost estimates for screening
and 3 years of management in a system
with Medicare fee-for-service reimburse-
ment rates, with 70% speciﬁcity cutoffs,
and assuming that false-negative costs
(thatcouldbepreventedafterdetectionof
dysglycemia) amounted to 10% of 3-year
medical costs. Cost components for these
cost estimates are described in detail in
online appendix Table A1. From both
perspectives, total costs for testing
(screening test  follow-up OGTT if in-
dicated) were lowest for RCG because it
was the least expensive test and had the
fewest positive screens. Total true-
positive costs were highest for GCT-pl
from both perspectives, due to the higher
numbers of true positives detected, while
the cost of false negatives was highest for
RCG because this test had the highest
number of false negatives.
Total health system costs for all study
subjects using base case assumptions
would be GCT-pl $180,635, GCT-cap
$182,980, RPG $182,780, RCG
$186,090, and A1C $192,261; all were
less than the cost of no screening, which
was $205,966, with GCT-pl being the
least expensive test. Societal costs with
the same assumptions were GCT-pl
$272,839, GCT-cap $269,414, RPG
$268,630, RCG $267,201, and A1C
$279,436; all were close to the cost for no
screening, which was $269,261, with
RCG being the least expensive test and
slightly less expensive than no screening.
However, GCT-pl was the least expensive
test from both perspectives when costs
were compared per true positive identi-
ﬁed (Table 1).
Sensitivity analyses
Fig. 1 shows varied fractions of false-
negative costs from health system and so-
cietal perspectives. When false-negative
costs were over 10% of 3-year projected
marginalcostsforpre-diabetesanddiabe-
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jected costs for screening and
managementwouldbelowerthancostsof
no screening. When false-negative costs
were less than 10% (the DPP false-
negative cost was slightly greater than
5%),costsforscreeningandmanagement
wouldbemorethanthecostofnoscreen-
ing. For false-negative costs higher than
10%, GCT-pl was the least expensive test
from both perspectives, while for frac-
tionslessthan10%,RCGwasleastexpen-
sive. False-negative costs contributed
most to total costs when higher fractions
were used, while true-positive costs con-
tributed more when lower fractions were
used (online appendix Figure A1).
In the sensitivity analyses (Table 2),
from a health system perspective, GCT-pl
screening would be the least expensive
test in most of the scenarios described.
These scenarios include use of a glucose
cutoff for pre-diabetes based on the opti-
mality criterion, longer staff time for ad-
minstering the screen, higher rates of
progression from pre-diabetes to diabe-
tes, and higher and lower prevalence of
disease. From a societal perspective (Ta-
ble2),theleastexpensivetestvariedmore
depending on the scenario but tended to
be either GCT-pl or RCG.
We examined potential single-payer
system costs, using VA-based costs as an
example. Using base case assumptions,
with VA costs for testing and metformin,
health system costs for all tests would be
less than costs for no screening, with
GCT-pl being the least expensive test. So-
cietal costs for all tests would also be less
than no screening, with GCT-cap being
least expensive. If VA-TP costs were used,
the costs for screening with any of these
tests would be substantially less than the
costofnoscreening,assumingeitherbase
case 10% false negative or DPP-false-
negative costs, and GCT-pl would be the
least expensive test (Table 2 and online
appendix Figure A2).
Lifestyle intervention costs, using
Medicare testing costs, 10% false-
negative costs, and costs for a group in-
tervention derived from the DPP, were
similar from a health system perspective
to the costs for treatment with generic
metformin: screening with any test was
less expensive than no screening, with
GCT-pl being the least expensive test. So-
cietal costs were much higher than costs
for no screening and higher than costs as-
sociated with treatment with metformin
due to the signiﬁcant direct nonmedical
costs associated with the lifestyle
intervention.
There has been recent interest in us-
ing A1C as both a screening and a diag-
nostic test for diabetes. We calculated the
costs of using A1C 6.0–6.4% to diagnose
pre-diabetesandA1C6.5%todiagnose
diabetes, without conﬁrmatory testing.
Health system costs, with our base case
assumptions and using metformin and
lifestyle modiﬁcation for management,
would be $226,122 and $225,944, re-
spectively—both higher than the costs
with GCT or random glucose testing and
higher than the cost of no screening, be-
cause of a large number of false negatives
and treatment of false positives. Societal
costs with metformin and lifestyle modi-
ﬁcation management would be $299,524
and $411,726, again higher than with
otherscreeningtestsorwithnoscreening.
CONCLUSIONS — Thisstudyevalu-
ated the economic justiﬁcation for a
screeningprogramthatwoulddetectboth
pre-diabetes and previously unrecog-
nized diabetes. Over a 3-year horizon
(typical of the duration of employer
health insurance coverage for many
workers), we compared the costs of no
screening to the costs of screening with
RPG, RCG, or A1C available today as well
as novel GCT-pl and GCT-cap tests, and
included the costs of management of de-
tected cases. With Medicare-based costs
and our base case assumptions, screening
would be less expensive than no screen-
ing from a health system perspective and
cost neutral or only slightly more expen-
sivethannoscreeningfromasocietalper-
spective; these results were robust to a
variety of sensitivity analyses. GCT-pl
screening had the greatest diagnostic ac-
curacy, and, in many scenarios, would
provide the lowest health system costs.
Thesensitivityanalysesperformedin-
clude a wide range of assumptions and
twoendsofthespectrumofhealthsystem
costs for treatment with metformin,
Medicare-andVA-based.Inbothsettings,
the costs of testing would be only a minor
Figure 1—Health system and societal costs associated with varied fractions of false-negative
costs. Total health system and societal costs for each screening test and for no screening, which
include costs of testing, false negatives, and treatment of true positives, assuming different frac-
tions of false-negative costs that could be prevented with early detection of conditions.
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with RCG would be least expensive. With
more accurate tests (GCT-pl is best, RCG
worst), the costs of true positives would
rise and the costs of false negatives would
fall. Overall, GCT-pl screening would be
least expensive in settings with CMS re-
imbursement rates as well as in VA-based
settings.
We estimated costs for treatment of
true positives, both with metformin and
lifestyle modiﬁcation, based on the treat-
ment protocol used in the DPP, but sub-
stituted drug costs to reﬂect current
prices. However, some have suggested
thatsuchinvolvedtreatmentmightbeim-
practical to implement in real-world set-
tings. Recognizing this, we also examined
an alternative care system: the VA. Costs
in the VA are lower than Medicare testing
and retail drug costs and might be repre-
sentative of costs with a single-payer
healthcare system. With these costs
(VA-TP costs), screening with any of the
tests would be cost-saving from both
health system and societal perspectives.
Our analyses also revealed that
screening for pre-diabetes and diabetes
would involve a high cost for false nega-
tives—a high cost for undetected and un-
treated pre-diabetes and diabetes. This
was not unexpected, since costs attribut-
able to diabetes (before and after diagno-
sis) are substantial due to a combination
ofcostsofhospitalizationsrelatedtocom-
plications (particularly cardiovascular
disease), pharmacy costs, and other med-
ical visits (18–20,22,23).
Theﬁndingthattreatmentofdetected
cases might be cost-saving from a health-
systemperspectiveisatleastpartlydriven
by the ﬁndings from the DPP study in
which those participants who were
treated with metformin or lifestyle
changes had reduced medical costs out-
sideofthestudycomparedtothoseinthe
placebo arm. We do not have a mecha-
nism through which these cost-savings
were obtained, but they may have re-
sulted from improvements in cardiovas-
cular risk factors which have been
associated with both types of treatment.
Our study has limitations. The study
subjectswerevolunteers,whichmayhave
caused some selection bias. However, the
prevalenceofpre-diabetesanddiabetesin
our study is similar to that found in other
studiesandlowercomparedtorecentNa-
tional Health and Nutrition Examination
Survey(NHANES)estimates(24).Wedid
not consider screening with fasting
plasmaglucoseinthisstudy;however,ac-
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health system costs should be similar to
those with RPG testing, so costs should
still be favorable compared to no screen-
ing.TheADA(25)hasrecommendedthat
A1C be used for the diagnosis of diabetes
and pre-diabetes, so screening with A1C
measurements might involve either no
follow-up testing or at most a repeat A1C
if the ﬁrst A1C were high, which differs
from our main analysis, in which fol-
low-up testing would involve an OGTT.
Since A1C is a relatively inaccurate
screening test, especially for pre-diabetes
(13), an A1C-only screening strategy
would increase screening costs but de-
crease both the projected costs for treat-
ment (because fewer positives would be
found), and the costs we attributed to pa-
tientswhowereA1C-negativebutOGTT-
positive (by deﬁning such patients as true
negatives). However, such an approach
ignores the empirical ﬁndings of in-
creasedcostsassociatedwithpre-diabetes
(above).
Our analysis also assumed that all
adults would be screened for pre-
diabetes/diabetes. If, however, screening
targeted adults with one or more risk fac-
tors,theoverallscreeningcostswouldde-
crease (due to fewer numbers being
screened), and the relative proportion of
true positives to false negatives should
rise. In this case, the cost-effectiveness of
screening should improve (7), and the
costs of screening and 3 years of manage-
mentshouldbecomeevenmorefavorable
relative to no screening, since the cost of
treatment of true positives, in our estima-
tion, is less than the average cost of false
negatives.
We focused our analysis on costs re-
lated to treatment with metformin, but
this may not be the best treatment. Life-
style interventions emphasizing diet and
weight loss are a better treatment from a
medical and, possibly, also from a cost
perspective(12,16).However,metformin
is a treatment that can be implemented in
aconsistentmannerbymostpractitioners
withfairlypredictableresults.Finally,the
scopeofourstudywaslimitedtothecosts
of one-time screening and did not incor-
porate the lifetime modeling needed to
determine if the cost-savings we project
over a 3-year period would continue with
a program of repeated screening, as cur-
rently recommended by the ADA and
theCentersforDiseaseControlandPre-
vention. However, a 3-year period
might be an ideal representation from
the perspective of a payer working with
employers whose employees come and
go, and who change healthcare plans
every few years.
Our analyses indicate that screening
programs and 3 years of management for
pre-diabetes and previously unrecog-
nized diabetes should be cost-effective,
particularlyfromahealthsystemperspec-
tive, and may be cost-saving.
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